ArticleEuropean journal of medical research2025
Development and validation of a novel frailty model for the patients with newly diagnosed multiple myeloma.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
backgroundThe predominance of ageing in patients with multiple myeloma (MM) results in at least 30% of patients being classified as frail at diagnosis. Compared with healthy individuals, frail individuals exhibit reduced treatment tolerance and lower quality of life, which are correlated with decreased survival rates. Although various frailty models for MM have been developed, challenges remain in their broad application and timely adjustment of treatment based on frailty evaluations across heterogeneous patient groups.
methodsThis retrospective study analysed data from 606 patients with newly diagnosed MM at Xijing Hospital between May 2006 and August 2022. The dataset was randomly divided into a development set (N = 424) and a validation set (N = 182). A novel frailty model (Fmodel) was developed using LASSO regression, random survival forest, and both univariate and multivariate Cox regression analyses. The model can predict overall survival (OS) and progression-free survival (PFS) in patients with MM while distinguishing frail subgroups. Its performance was compared with the previously established frailty model (Smodel) and the Revised International Staging System (RISS).
resultsThe Fmodel incorporates five variables: age, HCT-CI, ECOG-PS, ISS, and PNI. It stratified patients into three categories: fit, intermediate fit, and frail. Compared with the Smodel and RISS, the Fmodel exhibited robust discrimination and stability in predicting OS and PFS in both the development and validation sets and demonstrated superior calibration, discrimination, clinical applicability, and predictive ability. Frail patients were found to be at a greater risk for grade ≥ 2 nonhematologic adverse events (AEs) when receiving conventional-dose treatment (p < 0.05). Furthermore, the Fmodel provided accurate predictions of early mortality in patients with MM.
conclusionWe developed a novel frailty model for patients with MM based on age, HCT-CI, ECOG-PS, ISS, and PNI, effectively identifying the frail population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.